LARTRUVO
PeakmAbBLAInjectionInjectablePriority Review
Approved
Oct 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARTRUVO is a monoclonal antibody (mAb) therapeutic developed by Eli Lilly and approved in October 2016. The specific indication and mechanism of action are not publicly detailed in available data, though the injectable formulation suggests a serious systemic condition. As a biologic, it requires specialized manufacturing, distribution, and clinical support infrastructure.
Peak
Product is in peak commercial lifecycle stage, suggesting established market presence and stable team structure with mature demand.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARTRUVO is a mature peak-stage biologic with limited publicly linked job openings, indicating a stable, established brand team. Career opportunities focus on defending market position, patient support, and reimbursement rather than growth-phase expansion.
Brand ManagerMedical Science Liaison
Worked on LARTRUVO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.